-transparent.png){kind=logo}
Patients with the barbiturate abstinence syndrome require pharmacotherapy (and hospitalization) when there is a history of the ingestion of greater than 0.4 g of secobarbital or its equivalent for 90 or more days, or of 0.6 g for 30 or more days, or a previous history of barbiturate withdrawal seizures or delirium. The pharmacological management of withdrawal, which is rational, safe, efficacious and relatively simple, is described and recommended. This treatment relies on a phenobarbital loading-dose technique which is titrated to clinical end-points. The prolonged elimination of phenobarbital prevents the reappearance of withdrawal symptoms and, since repeated doses are not required, results in less manipulative drug-seeking behaviour.
J T Sullivan, and
E M Sellers
July 1980,
JAMA,
J T Sullivan, and
E M Sellers
July 1950,
Annals of internal medicine,
J T Sullivan, and
E M Sellers
October 1963,
The American journal of psychiatry,
J T Sullivan, and
E M Sellers
November 1954,
The Journal of pharmacology and experimental therapeutics,
J T Sullivan, and
E M Sellers
September 1972,
Neuropharmacology,
J T Sullivan, and
E M Sellers
January 1953,
Research publications - Association for Research in Nervous and Mental Disease,
J T Sullivan, and
E M Sellers
January 1999,
Journal of pediatric health care : official publication of National Association of Pediatric Nurse Associates & Practitioners,
J T Sullivan, and
E M Sellers
January 2003,
Archives of disease in childhood. Fetal and neonatal edition,
J T Sullivan, and
E M Sellers
July 2005,
Archives de pediatrie : organe officiel de la Societe francaise de pediatrie,
